Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

Wolfgang Eiermann, Tadeusz Pienkowski, John Crown, Saeed Sadeghi, Miguel Martin, Arlene Chan, Mansoor Saleh, Sandeep Sehdev, Louise Provencher, Vladimir Semiglazov, Michael Press, Guido Sauter, Mary Ann Lindsay, Alessandro Riva, Marc Buyse, Philippe Drevot, Henry Taupin, John R. Mackey

Research output: Contribution to journalArticlepeer-review

132 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science